日期: 2026 年 3 月 3 日

TANAKA Establishes Transfer Technology for its Sintered Gold (Au) Bonding Technology “AuRoFUSE(TM) Preforms”

jcn

TOKYO, Mar 3, 2026 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Head office: Chuo-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), a company engaged in the industrial precious metals business of TANAKA, today announced a gold bump*1 transfer technology for the sintered gold (Au) bonding technology “AuRoFUSE™ Preforms.” This technology allows AuRoFUSE™ Preforms (gold bumps) to be formed even on semiconductor chips and substrates*2 with complex structures.Gold bump transfer substrate producedGold bumps after transferAdvantages of being able to transfer gold bumpsIn this technology, at first, gold bumps are formed on a substrate (transfer substrate). Then, the gold bumps are transferred to the target semiconductor chip or substrate. Openings are created on the silicon substrate used as the transfer substrate, and gold bumps are formed in them. By filling the entire opening, the gold bump is held by the substrate, eliminating the risk of dropping during the process. Meanwhile, during transfer, the gold bump shrinks under heat-treatment, forming a tiny gap between the opening and the gold bump. This allows easy extraction of gold bumps by the application of a force in the vertical direction.As the traditional gold bump formation process is a method that directly forms bumps on the target semiconductor chip or substrate, it is difficult to handle target chips and substrates with complex shapes, such as protrusions, dents, or open holes due to issues such as inconsistent resist heights.In this current transfer technology, gold bumps are manufactured separately and can be transferred only to the target locations. This allows the technology to also be applied to complex shapes. It can also be used with semiconductor chips and substrates that are difficult to process using photolithography*3 due to concerns about damage from stripping solutions and others.Manufacturing of transfer substrate and transfer and bonding process(1) Preparation of silicon substrate as transfer substrate(2) Application of photoresist to silicon substrate(3) Exposure and development of target pattern(4) Etching of silicon substrate to create holes(5) Application of AuRoFUSE™ using a squeegee, etc.(6) Vacuum drying of AuRoFUSE™ at room temperature and scraping off excess gold particles on the resist(7) Removal of resist to complete transfer substrate(8) Placement of transfer substrate on target (semiconductor chip or substrate) for gold bump formation, thermocompression at 10 MPa and 150℃ for one minute, followed by vertical lifting of substrate to transfer gold bumps(9) Bonding of post-transfer target through thermocompression at 20 MPa and 200℃ for 10 secondsAn illustration of the traditional gold bump formation process is available in the “Manufacturing of AuRoFUSE™ Preforms” section for reference on TANAKA’s website.About the sintered gold bonding technology “AuRoFUSE™ Preforms”Developed by TANAKA, “AuRoFUSE™ Preforms” is a bonding technology that forms bumps of all kinds of shapes using a paste comprising gold particles and an organic solvent. Through a thermocompression bonding process (20 MPa at 200℃ for 10 seconds), AuRoFUSE™ Preforms exhibits compression of approximately 10% in the compressive direction while showing minimal deformation in the horizontal direction. This gives them sufficient bonding strength*4 for practical applications. With the main component being gold, which has a high level of chemical stability, AuRoFUSE™ Preforms also provides excellent reliability after mounting.This technology enables miniaturization of semiconductor wiring and greater integration (higher density) for various types of chips. It is expected to contribute to the needs for miniaturization and better performance of semiconductors, which have been rising in recent years, including optical devices such as light-emitting diodes (LEDs) and semiconductor lasers (LDs), use in digital devices such as personal computers, smartphones, as well as in-vehicle components, micro-electromechanical systems (MEMS), and such.Traditionally, the main methods used in bump formation technology are soldering and plating. However, as solder tends to spread outward in molten state, there was the risk of short-circuiting through contact between electrodes as the bump pitch becomes finer. Meanwhile, plating can achieve a fine pitch, but because comparatively higher pressures are required during bonding, there is the possibility of causing chip damage. For reference, an illustration outlining the advantages of this technology compared with soldering and plating materials is provided in the “Comparison of AuRoFUSE™ Preforms with Other Materials” section on TANAKA’s website. This technology was developed to address these issues for use in next-generation high-density mounting and photonics-electronics integration devices.AuRoFUSE™ and TANAKA’s gold materialsAuRoFUSE™ is a paste-type bonding material containing a mixture of gold particles, with the particle diameter controlled to be submicron sized, and an organic solvent. Compared to the melting point of gold (approximately 1,064℃), bonding is possible at a low temperature of approximately 200℃.Gold is a material with low electrical resistance and extremely high thermal conductivity. Therefore, in power semiconductors that handle large currents and high-density chips that dissipate a lot of heat, it can efficiently dissipate heat and limit energy loss. Among precious metals, it is also particularly resistant to oxidation and has stable properties, making it less susceptible to corrosion after mounting and ion migration (a phenomenon in which metals move and cause short circuits). This allows it to maintain high reliability over long periods of time.TANAKA is highly skilled in precious metal material development technologies, developed since its establishment. It has used these technologies to undertake development of precious metal materials, such as gold, which plays a key role in the semiconductor field. With a system that integrates the entire chain of processes, from raw material procurement to material development, manufacturing, and recycling, TANAKA will contribute to the development of semiconductor technologies and the realization of a sustainable society while effectively using limited precious metal resources.*1 Bumps: Protruding electrodes*2 Substrate: Board that electrically and mechanically supports semiconductor chips mounted on it*3 Photolithography: Technology for forming fine circuit patterns on substrates*4 Bonding: Refers to shear strength (strength determined through application of a lateral load during testing)About TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group’s consolidated net sales for the fiscal year ended December 2024 were 846.9 billion yen.TANAKA Industrial Precious Metal Materials Portalhttps://tanaka-preciousmetals.comProduct inquiriesTANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-on-industrial-products/Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/Press Release: https://www.acnnewswire.com/docs/files/20260303_EN.pdf  Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

五礦資源公佈2025年年度業績 業績創歷史新高 發展動能強勁

acn

香港, 2026年3月3日 - (亞太商訊 via SeaPRwire.com) - 五礦資源有限公司（「MMG」；股份代號：1208）今日發佈二零二五年年度業績，營業收入與利潤均創歷史新高。這一優異成績，體現了公司卓越的運營與財務管理，同時受益於有利的商品價格。觀看五礦資源行政總裁趙晶先生致辭視頻：https://drive.google.com/file/d/1iini4Eu_ACtpHlC9E6i6B5P2k6qntUJu/view?usp=sharing安全始終是五礦資源的首要價值。2025年全年，公司可記錄總工傷事故頻率（TRIF）為每百萬工時2.06。具有能量交換的重大事件頻率（SEEEF）為每百萬工時0.80，較2024年的0.78略有上升。公司總體盈利水平創歷史新高。EBITDA 達到 34.12 億美元，EBIT 增至 19.99 億美元。五礦資源同時實現創紀錄的經營活動現金流淨額 26.90 億美元、自由現金流 16.08億美元。稅後淨利潤增至 9.55 億美元（包括權益持有人應佔利潤 5.09 億美元），較 2024 年的 3.66 億美元（包括權益持有人應佔利潤 1.62 億美元）大幅增長。五礦資源行政總裁趙晶先生表示：「公司全年業績強勁收官，運營和財務表現都十分出色。其中Las Bambas礦山實現了有史以來第二高的年度銅產量，較2024年增長27%，並在年採礦量、選礦量及總回收率上均創下紀錄。」五礦資源的資產負債表大幅增強，淨負債進一步下降，槓桿率降至33%的歷史低位。這部分得益於Las Bambas合營公司的股息分配，幫助公司提前償還了Khoemacau 項目 5 億美元貸款。剩餘資金用於償還其他債務、降低公司槓桿水平，並支持 Khoemacau 擴建項目的前期工作。得益於技術、創新以及Las Bambas兩個採場的穩定運營，五礦資源 銅總產量同比增長 27%，達到 506,899 噸。2025 年Las Bambas實現收入 44.47 億美元（同比增長 49%），是公司收入增長的最大貢獻來源。鋅總產量增長 6%，達到 232,060 噸，主要得益於Dugald River礦山的創紀錄表現。Rosebery礦山的貴金屬產量同樣表現良好。趙先生表示：「我們會持續關注變化的市場環境，同時專注推進增長計劃，並通過運用新興技術為股東創造長期價值。Khoemacau 擴建項目是 五礦資源 增長戰略的重要一環。我們計劃在 2028 年將銅精礦含銅的年產能提升至 13 萬噸，並在未來有望達到 20 萬噸。」2025 年，公司市值超過 1,000 億港元，首期可轉換債券也獲得強勁認購。五礦資源 2025 年年度業績報告可點擊此處查閱。Las BambasKhoemacauDugald RiverRoseberyKinsevere按此下載新聞稿圖片：https://drive.google.com/drive/folders/1o9ArIgbJSAT2z1UCt8ttB69L9l9jiebx?usp=drive_link關於MMG五礦資源成立於二零零九年，其願景是為低碳未來打造國際領先的礦業公司。公司總部位於澳大利亞墨爾本和中國北京，並在香港聯合交易所上市（聯交所：1208）。五礦資源的資產組合涵蓋銅、鋅和鈷的生產，並即將拓展至鎳領域。這些金屬資源對全球脫碳和電氣化目標的實現至關重要。目前，公司的運營業務遍佈澳大利亞、博茨瓦納、剛果民主共和國及拉丁美洲，為所在國家的經濟與社會發展作出直接貢獻。2025 年，五礦資源發佈了首份自然戰略，並推進氣候戰略的更新工作。五礦資源加入聯合國全球契約組織（UN Global Compact），進一步使公司在人權、氣候行動及公司治理等方面與全球領先水平保持一致。更多信息請點擊此處。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Fujitsu and BCN Port Innovation Foundation leverage ocean digital twin technology to drive the regeneration of the Port of Barcelona

jcn

Kawasaki, Japan and Barcelona, Spain, March 3, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu and BCN Port Innovation Foundation today announced a new agreement between Fujitsu Spain and the BCN Port Innovation Foundation to develop a proof of concept (PoC) for an ocean digital twin at the Port of Barcelona. This pioneering initiative is aimed at the regeneration of the marine environment, the protection of biodiversity and the promotion of the blue economy(1).Catalina Grimalt, CEO and President, BCN Port Foundation (left) and Ángeles Delgado, President of Fujitsu Technology Solutions S.A. (right) shaking hands after the signing ceremony to kick off the proof of concept.The project is based on the use of underwater drones combined with artificial intelligence and advanced analytics, capable of capturing high-resolution representations of the seabed. Using this non-destructive sensing approach, the digital twin will make it possible to visualize and quantify biodiversity, calculate biomass based on vegetation cover, and estimate blue carbon(2) associated with marine algae.This project lays the foundations for the BCN Port Innovation Foundation to have a unified digital platform that centralizes all information on port biodiversity and enables its long-term monitoring.With this initiative, Fujitsu reinforces its commitment to developing proprietary technology with social and environmental impact, aligned with climate neutrality goals and the protection of marine ecosystems, and consolidates its role as a technology partner in sustainable innovation projects in Spain.Fujitsu and the BCN Port Innovation Foundation plan to carry out the proof of concept in the Port of Barcelona during 2026.A new approach to measuring and protecting marine biodiversityGlobal marine ecosystems face a severe crisis due to global warming and ocean pollution. The EU is accelerating marine environmental conservation and restoration efforts, notably with the 2024 adoption of the Nature Restoration Law, which mandates marine ecosystem recovery.By integrating AI-enabled underwater data capture with advanced analytics, the Ocean Digital Twin transforms how marine ecosystems are measured, understood, and utilized. Autonomous surface and underwater vehicles follow optimized survey routes with real-time stabilization control, enabling consistent and repeatable seabed data acquisition and generating high-quality data suitable for AI processing.Machine learning models convert this data into quantitative environmental intelligence, estimating vegetation coverage, assessing habitat extent, and calculating blue carbon absorption. The technology also provides precise spatial data on seabed conditions, habitat distribution, and species types, creating a strong empirical foundation for the design and evaluation of conservation, restoration, and regeneration projects.In addition, the system enables continuous monitoring of multiple plant species, making it possible to analyze ecosystem evolution over time and anticipate potential impacts resulting from both climate change and port activity.Figure: Ocean Digital TwinEnvironmental simulation and data-driven decision-makingThe platform developed by Fujitsu enables the simulation of “what if” scenarios, helping pre-verification of environmental measures before they are implemented to prioritize investments based on their real impact. Thanks to the creation of a high-fidelity digital model, port authorities can identify priority areas for protection, as well as zones suitable for environmental restoration or rehabilitation.This simulation capability makes the digital twin a key tool for balancing port activity with the preservation of the natural environment, facilitating the design of more sustainable infrastructure and operations. Following a successful PoC, Fujitsu and BCN Port Innovation Foundation can collaborate to add regeneration and preservation simulation scenarios to the project.Blue economy, transparency and social engagementBeyond environmental conservation, the project could open up new opportunities within the blue economy, facilitating the potential development of marine research initiatives, environmental education and scientific outreach activities.Moreover, the visual and immersive nature of the digital twin enhances transparency and awareness, helping to bring knowledge of the marine environment closer to stakeholders and fostering greater understanding of the importance of protecting coastal ecosystems.Ángeles Delgado, president of Fujitsu Spain and Portugal, points out: “This project demonstrates how technology can become a true ally of sustainability. The ocean digital twin allows us to transform complex data from the marine environment into actionable information to protect biodiversity, promote blue carbon initiatives, and make evidence-based decisions.”(1) Blue economy:Achieving economic growth, job creation, and environmental preservation simultaneously while sustainably utilizing marine resources.(2) Blue carbon:Carbon captured by coastal and marine ecosystems through photosynthesis and subsequently stored in seabeds and deep seas.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuAbout BCN Port InnovationBCN Port Innovation is a public-private collaboration initiative between the Port of Barcelona and the enterprise ecosystem aimed at promoting and validating innovative solutions in areas such as the logistics and port processes, mobility, and the energy transition, with a cross-cutting focus on digitalization and sustainability. More information: https://bcnportinnovation.org/en/Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesBCN Port InnovationMar Fernándeze-mail: m.fernandez@bcnportinnovation.org  Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

MiniMax官宣向AI平台型公司邁進 ARR超1.5億美金夯實底盤

acn

香港, 2026年3月3日 - (亞太商訊 via SeaPRwire.com) - 3月2日，MiniMax（股票代碼：00100.HK）發佈2025年全年業績公告，同時披露2026年開年以來的強勁增長表現，2026年2月公司年度經常性收入（ARR）突破1.5億美元，迎來業務發展的重要躍升。財報數據顯示，MiniMax2025年總營收達7903.8萬美元，同比增長158.9%，業務板塊均實現高速增長。其中AI原生產品收入5307.5萬美元，同比增143.4%；開放平台及企業服務收入2596.3萬美元，同比增幅達197.8%。全球化佈局成效顯著，該年度公司國際市場收入占比73%，已服務全球200餘個國家和地區的2.36億用戶，以及21.4萬企業客戶與開發者。2026年開年，MiniMax增長態勢進一步提速，2月開放平台新註冊用戶數較2025年12月超4倍增長，M2系列文本模型平均單日Token消耗量增幅超6倍，其中Coding Plan相關Token消耗增長更是突破10倍。在此背景下，公司正式宣佈從大模型企業向AI時代平台型企業邁進，並將AI平台價值定義為「智能密度 × Token 吞吐量」，錨定兩大核心指標構建平台化能力。針對2026年AI行業趨勢，MiniMax作出三大判斷，認為編程領域將迎來L4-L5級智能，實現從工具到同事級的協作升級；辦公領域AI智能體的交付與滲透速度將大幅提升；多模態創作則將實現可交付中長內容的直出，甚至走向實時輸出形態，而三大趨勢疊加或將推動Token量級實現1-2個數量級的增長。目前公司已啟動M3及Hailuo 3系列模型研發，同時內部AI原生組織實踐落地，超90%員工日常工作場景覆蓋內部Agent，為模型迭代提供直接反饋。業績增長的同時，MiniMax的盈利與研發效率也同步提升。2025年公司毛利額約2007.9萬美元，同比大增437.2%，毛利率從2024年的12.2%提升至25.4%，核心得益于推理成本的持續下降，2026年2月M2系列文本模型每百萬Token推理算力成本較2025年12月下降超50%。費用結構也持續優化，研發費用同比增33.8%的同時，營銷費用同比下降40.3%。此外，MiniMax的全模態技術能力持續夯實，2025年108天內完成M2系列三版模型迭代，視頻、語音模型分別累計生成超6億個視頻、2億小時語音，為跨模態融合奠定基礎。憑藉成熟的商業化路徑、持續優化的成本結構與全球化商業生態，MiniMax已初步夯實AI平台型公司的戰略定位，為迎接新一輪行業智能紅利做好充分準備。公司創始人、CEO閆俊傑表示，MiniMax 將始終以技術創新為核心，持續提升智能密度與Token吞吐效率，以平台化能力攜手全球客戶與開發者，共同挖掘AI時代的全新商業價值。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

如祺出行 (9680.HK) 盈喜：預計 2025 年收入增超 100%，盈利承諾加速兌現

eqs

EQS via SeaPRwire.com / 2026-03-03 / 17:42 UTC+8 3 月 3 日，如祺出行（9680.HK）發布正面盈利預告。公司預計 2025 年度利潤同比大幅改善不少於 43.4%，綜合收入不少於人民幣 50 億元，同比大幅增長不少於 100%。 公告顯示，如祺出行 2025 年度綜合收入增加主要得益於網約車訂單量顯著增長，以及由於公司加大技術服務銷售及營銷力度帶來技術服務收入增長。而盈利大幅改善則主要由於網約車運營效率提升及成本結構優化、技術服務業務量增加等綜合因素，共同推動毛利增長。此外，公司預計 2025 年度行政開支及財務成本均同比減少。 這是如祺出行在 2024 年 7 月登陸港交所後首次公布盈利預告，也是目前港股已上市出行平台公司中首個發布正面盈利預告的公司。市場分析認為，相關表現顯示公司逐步兌現關於「擴大業務規模、促進收入增長、提高毛利率」等盈利承諾，盈利向好的速度優於市場預期。   2026-03-03 此財經新聞稿由EQS via SeaPRwire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php

華領醫藥宣佈多格列艾汀在中國香港獲批上市

acn

- 中國內地以外首款獲批的葡萄糖激酶激活劑（GKA）- 本次獲批為2型糖尿病的差異化治療提供新方案- 中國香港將成為華領醫藥國際化市場拓展的重要起點上海，香港, 2026年3月3日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（「公司」，香港聯交所股份代號：2552）今日宣佈，其全球首創新藥葡萄糖激酶激活劑（GKA）多格列艾汀（dorzagliatin）（商品名：MYHOMSIS(R)，華領片(R)）已獲中國香港特別行政區政府衛生署藥物辦公室批准上市，用於治療成人2型糖尿病。依託香港優化的「1+」藥物監管創新機制，2025年9月，香港衛生署正式受理多格列艾汀的新藥上市申請（NDA），作為「1+」機制開展以來，首個獲批上市的慢性代謝病創新藥，多格列艾汀的成功落地不僅為香港地區2型糖尿病患者帶來全新治療選擇，更標誌著華領醫藥以香港為樞紐，從中國正式進軍東南亞及全球市場的戰略佈局已邁出關鍵一步。華領醫藥集團運營和大灣區發展部副總裁曹蓓莉介紹：「本次在『1+』機制下獲批的三個新藥中，華領片(R)是獲得中國國家藥品監督管理局批准的中國創新藥，也是『1+』機制下獲批的首個普藥。」華領醫藥創始人、執行董事兼CEO陳力博士表示：「多格列艾汀在香港的獲批上市，是公司發展歷程中的重要里程碑。作為香港『1+』機制下獲益的首批原研創新藥，這一成果不僅體現了香港對創新藥的支持，更驗證了中國自主研發創新藥的全球競爭力。香港上市是華領醫藥進軍東南亞及國際市場的關鍵一步，我們將以香港為樞紐，構建輻射東南亞、連接全球的營銷網絡與研發合作體系，讓中國自主研發的創新藥惠及更多國家和地區的糖尿病患者。同時，我們將持續推進多格列艾汀在中國澳門特別行政區的上市進程，實現其在粵港澳大灣區的全面落地，並依託此區域政策人才和醫療資源優勢，推進新適應症的臨床拓展和華領片(R)的國際推廣。」全球首創+成熟臨床數據，建立重塑血糖穩態治療新範式2型糖尿病是一種進展性疾病，其核心特徵是人體血糖調節功能受損，胰島β細胞功能也會隨著病程進展逐步衰退。當前多數治療方案僅針對血糖紊亂引發的下游症狀進行干預，多格列艾汀是華領醫藥自主研發的全球首創GKA類新藥，其核心創新在於通過修復2型糖尿病患者受損的葡萄糖激酶（GK）功能和表達，從源頭上提升患者的葡萄糖敏感性，改善血糖穩態失調。該藥物可作用於胰島、腸道、肝臟等多個葡萄糖代謝關鍵器官，通過多靶點協同作用：- 促進胰島β細胞在血糖刺激下分泌胰島素；- 促進腸道L細胞分泌胰高血糖素樣肽-1（GLP-1）；- 通過調節肝糖原代謝，調控肝臟的葡萄糖輸出這種多器官協同的作用特徵，讓多格列艾汀區別於現有口服降糖藥物，也體現出華領醫藥從源頭改善血糖穩態失衡問題，控制2型糖尿病的進展及其併發症發生的研發核心思路。多格列艾汀於2022年9月獲得中國國家藥品監督管理局（NMPA）的上市批准，獲批兩個適應症：1）單獨用藥治療未經藥物治療的2型糖尿病患者，可以用於一線治療；2）在單獨使用鹽酸二甲雙胍血糖控制不佳時，與鹽酸二甲雙胍聯合使用，改善成人2型糖尿病患者的血糖控制。自2024年1月1日起，多格列艾汀已被納入《國家基本醫療保險、工傷保險和生育保險藥品目錄》，截至目前，中國大陸已有超 20 萬名患者使用該藥物。去年6月，在美國糖尿病協會（ADA）科學年會上發表的真實世界研究中期分析，進一步驗證了其在廣泛人群中的有效性與安全性。借力香港「1+」政策，創新藥加速惠及港民香港「1+」藥物監管創新機制的制定與實施，是香港特區政府為提升醫療創新可及性、吸引全球優質創新藥落地推出的重要舉措。該政策允許已在指定主要市場（如中國內地、美國、歐洲等）獲批的創新藥，通過簡化的申報路徑和數據互認機制，快速在香港完成上市審批，大幅縮短創新藥從研發到惠及香港患者的時間週期，同時保障藥品的安全性與有效性。多格列艾汀憑藉其在中國內地的成熟臨床數據、明確的治療價值及良好的安全性記錄，成為通過香港「1+」機制快速獲批的首批中國原創新藥。此次獲批是該政策賦能全球創新藥落地香港的重要實踐成果，不僅體現了香港衛生署對多格列艾汀臨床價值的高度認可，更彰顯了「1+」機制在連接內地與國際醫藥市場、加速創新醫療資源流動方面的核心作用。立足香港經驗，賦能全球糖尿病管理糖尿病是全球公共衛生領域的重大難題。國際糖尿病聯盟（IDF）2025年發佈的全球糖尿病地圖顯示，2024年，全球20-79歲的成年人中，糖尿病患者人數高達5.89億，預計到2050年，這一數字將攀升至8.53億。在中國香港地區，糖尿病也是一個突出的公共衛生問題。根據香港衛生署2020-2022年度人口健康調查，15歲或以上人士中，6.9%的人表示經醫生診斷患上糖尿病，另有1.8%有高血糖但並未患上糖尿病。2022年，香港因糖尿病導致的死亡登記人數超過600人，在主要死因中排名第十一位。​[1]香港在糖尿病管理方面擁有豐富經驗，形成了涵蓋疾病監測、預防、篩查、治療及社區管理的完善體系，其社區為本的公私營協作糖尿管理模式成效顯著。多格列艾汀在香港上市後，預計將與當地成熟的糖尿病管理體系深度融合，通過個性化治療方案助力提升患者生活質量、控制病情進展及減輕醫療負擔。目前，華領醫藥正在與國際著名內分泌專家、香港中文大學Juliana Chan教授團隊合作，開展SENSITIZE系列研究，以不斷探索多格列艾汀改善β細胞葡萄糖敏感性的作用機制。已經公佈的SENSITIZE1/2研究顯示，多格列艾汀可以顯著改善葡萄糖激酶單基因遺傳突變糖尿病 (GCK-MODY或MODY-2)患者的胰島素第二時相分泌和β細胞葡萄糖敏感性，可以顯著改善初發2型糖尿病患者的基礎胰島素分泌；多格列艾汀還可以顯著改善葡萄糖耐量異常（IGT）人群的二相胰島素分泌和β細胞葡萄糖敏感性。華領醫藥將繼續與本地頂尖科研機構和臨床醫生深度合作，進一步挖掘多格列艾汀在糖尿病前期干預、早期治療和併發症預防方面的潛力，積累更多國際化臨床數據，為其在全球範圍內的適應症拓展和市場推廣積累關鍵數據，並且建立糖尿病前期和2型糖尿病患者的個性化干預和治療管理方案。作為亞洲醫藥市場的核心樞紐，香港憑藉其獨特的地理位置、完善的醫療基礎設施、國際化的營商環境及與東南亞市場的緊密聯動優勢，有望成為華領醫藥進軍東南亞乃至全球市場的戰略起點。依託香港的藥品監管標準與國際接軌的優勢，利用香港的金融與資本市場優勢，華領醫藥將進一步推動多格列艾汀在東南亞市場的註冊申報，快速覆蓋該地區龐大的糖尿病患者群體。同時，深化與全球醫藥產業鏈夥伴的合作，加速推進多格列艾汀的國際化商業化進程。前瞻性聲明本文包含有關華領醫藥以及產品未來預期、計劃和前景的陳述。該等前瞻性陳述僅與本文作出該陳述當日的事件或資料有關，可能因未來發展而出現變動。除法律規定外，於作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請仔細閱讀本文並理解，由於各種風險、不確定性或其他法定要求我們的實際未來業績或表現可能與預期有重大差異。關於華領華領醫藥（「本公司」）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥彙聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品华堂宁(R)（多格列艾汀片）以葡萄糖傳感器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，华堂宁(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。2026年2月，多格列艾汀（商品名：MYHOMSIS(R)，華領片(R)）獲得中國香港特別行政區政府衛生署藥物辦公室的上市批准。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com[1] 2020-22年度人口健康調查報告書，中國香港衛生署衛生防護中心，https://www.chp.gov.hk/sc/features/37474.html Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

acn

- First glucokinase-activator (GKA) approval outside mainland China- Approval supports a differentiated approach to Type 2 diabetes (T2D) management- Hong Kong will serve as Hua Medicine’s launchpad for international market expansionSHANGHAI, HONG KONG, Mar 3, 2026 - (ACN Newswire via SeaPRwire.com) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS(R)) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.Under Hong Kong's "1+" pharmaceutical regulatory innovation mechanism, the approval follows the acceptance of dorzagliatin’s New Drug Application (NDA) by the Hong Kong Department of Health in September 2025. As the first innovative drug for chronic metabolic diseases approved for marketing since the launch of "1+" mechanism, the successful rollout of dorzagliatin not only brings an entirely new treatment option for patients with Type 2 diabetes in Hong Kong, but also marks a crucial step in Hua Medicine's strategic layout to expand from China to the Southeast Asian and global markets with Hong Kong as its hub.Cao Beili, Vice President of Department of Corporate Operation and Great Bay Development of Hua Medicine, stated: “Among the three new drugs approved under the ‘1+’ mechanism, MYHOMSIS(R) is an innovative medicine developed in China that has obtained approval from the National Medical Products Administration (NMPA). It is also the first primary care drug product approved under the ‘1+’ mechanism.”Dr. Chen Li, Founder, Executive Director and CEO of Hua Medicine, stated: "The approval of dorzagliatin for marketing in Hong Kong is a significant milestone in the Company's development. As one of the first original innovative drugs to benefit from Hong Kong's '1+' mechanism, this achievement not only reflects Hong Kong's support for innovative drugs, but also validates the global competitiveness of China's independently developed innovative drugs. The launch in Hong Kong is a key step for Hua Medicine to enter the Southeast Asian and international markets. We will take Hong Kong as the hub to build a marketing network and R&D cooperation system radiating Southeast Asia and connecting the world, bringing China's independently developed innovative drugs to more diabetes patients in countries and regions around the globe. Meanwhile, we will continue to advance the marketing approval process of dorzagliatin in the Macao Special Administrative Region of China to achieve its full rollout in the Guangdong-Hong Kong-Macao Greater Bay Area, and relying on the regional advantages in mechanisms, talent and medical resources, we will advance the clinical expansion of new indications and the international promotion of MYHOMSIS(R)."Global First-in-Class & Local Clinical Data: Establishing a New Model for Restoring Glycemic Homeostasis in Diabetes TreatmentType 2 diabetes remains a progressive disease characterized by impaired glucose regulation and declining pancreatic β-cell function over time. While many therapies address downstream consequences of dysregulated blood glucose, dorzagliatin is a global first-in-class GKA innovative drug independently developed by Hua Medicine. Its core innovation lies in repairing the impaired function and expression of glucokinase (GK) in patients with Type 2 diabetes, thereby improving patients' glucose sensitivity from the source and ameliorating the imbalance of glycemic homeostasis. The drug acts on multiple key organs of glucose metabolism including the islets, intestines and liver, exerting a synergistic effect through multiple targets:- enhancing glucose-stimulated insulin secretion from pancreatic β-cells, - promoting GLP-1 release from intestinal L-cells, and - modulating hepatic glucose output through glycogen regulation.This coordinated, multi-organ profile differentiates dorzagliatin from existing oral antidiabetic therapies and reflects Hua Medicine’s focus on addressing glucose homeostasis dysregulation and controlling the progression of Type 2 diabetes and the occurrence of its complications from the source.Dorzagliatin was approved for marketing by the China National Medical Products Administration (NMPA) in September 2022 for two indications, both to improve blood glucose control for T2D patients:1) It can be used as mono-therapy treatment for drug-naïve T2D patients, as first-line treatment,2) When metformin hydrochloride alone exhibits poor blood glucose control in T2D patients, it can be used in combination with metformin hydrochloride.Since January 1, 2024, dorzagliatin is included in China’s National Reimbursement Drug List and has been prescribed to over 200,000+ patients in mainland China already. In June last year, the interim analysis of real-world research presented at the Scientific Sessions of the American Diabetes Association (ADA) further verified its efficacy and safety in a broad population.Leveraging Hong Kong's "1+" Mechanism to Accelerate Access to Innovative Drugs for Hong Kong ResidentsThe formulation and implementation of Hong Kong's "1+" pharmaceutical regulatory innovation mechanism is an important measure taken by the Hong Kong SAR Government to enhance the accessibility of medical innovation and attract high-quality global innovative drugs to launch in Hong Kong. This mechanism allows innovative drugs already approved in designated major markets (such as China, the United States, Europe, etc.) to secure marketing approval in Hong Kong through a simplified application pathway and data mutual recognition mechanism, which greatly shortens the time cycle from R&D to clinical access of innovative drugs for Hong Kong patients, while ensuring the safety and efficacy of the drugs.With its local clinical data, clear therapeutic value and good safety record in China, dorzagliatin has become one of the first original Chinese innovative drugs to be rapidly approved through Hong Kong's "1+" mechanism. This approval is an important practical achievement of the mechanism in enabling the launch of global innovative drugs in Hong Kong, which not only reflects the high recognition of the clinical value of dorzagliatin by the Department of Health of Hong Kong, but also highlights the core role of the "1+" mechanism in connecting the Chinese market and international pharmaceutical markets and accelerating the flow of innovative medical resources.Building on Hong Kong's Experience to Empower Global Diabetes ManagementDiabetes is a major challenge for global public health.  According to the 2025 Global Diabetes Map released by the International Diabetes Federation (IDF), the number of adults aged 20-79 with diabetes worldwide reached 589 million in 2024, and this figure is projected to rise to 853 million by 2050.  In Hong Kong, China, diabetes is also a prominent public health issue. According to the Population Health Survey 2020-2022 conducted by the Department of Health of Hong Kong, 6.9% of people aged 15 or above reported having been diagnosed with diabetes by a doctor, and an additional 1.8% had hyperglycemia without being diagnosed with diabetes. In 2022, more than 600 death registrations in Hong Kong were attributed to diabetes, ranking 11th among the leading causes of death.[1]Hong Kong has accumulated rich experience in diabetes management, forming a comprehensive system covering disease surveillance, prevention, screening, treatment and community management, and its community-based public-private partnership model for diabetes management has achieved remarkable results. Following its launch in Hong Kong, dorzagliatin is expected to be deeply integrated with the local mature diabetes management system, and help improve patients' quality of life, control disease progression and reduce medical burdens through personalized treatment plans.At present, Hua Medicine is collaborating with the research team led by Professor Juliana Chan, a world-renowned endocrinologist from the Chinese University of Hong Kong, to conduct the SENSITIZE series of studies to further explore the mechanism by which dorzagliatin improves pancreatic β-cell glucose sensitivity. The published results of the SENSITIZE 1/2 studies have shown that dorzagliatin can significantly improve the second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2), and enhance basal insulin secretion in patients with newly diagnosed type 2 diabetes. In addition, dorzagliatin can also significantly improve the second-phase insulin secretion and β-cell glucose sensitivity in populations with impaired glucose tolerance (IGT).Hua Medicine will continue to deepen cooperation with top local research institutions and clinicians to further explore the potential of dorzagliatin in pre-diabetes intervention, early treatment and complication prevention, accumulate additional international clinical data, lay a solid foundation for the expansion of its indications and global market promotion, and establish personalized intervention and treatment management plans for patients with pre-diabetes and Type 2 diabetes.As a core hub of the Asian pharmaceutical market, Hong Kong, with its unique geographical location, advanced medical infrastructure, international business environment and close linkage with the Southeast Asian market, is expected to become the strategic starting point for Hua Medicine to expand into Southeast Asia and the global market. Relying on Hong Kong's advantage of pharmaceutical regulatory standards aligned with international norms and leveraging its financial and capital market strengths, Hua Medicine will further advance the registration and application of dorzagliatin in the Southeast Asian market to quickly cover the large population of diabetes patients in the region. Meanwhile, the Company will deepen cooperation with partners in the global pharmaceutical industry chain to accelerate the international commercialization of dorzagliatin.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS(R)) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail:pr@huamedicine.com[1] https://www.chp.gov.hk/sc/features/37474.html Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

愛康醫療(1789.HK)獲納入中證港股通機器人主題指數 凸顯機器人領域投資潛力

acn

香港, 2026年3月3日 - (亞太商訊 via SeaPRwire.com) - 上週五，中證指數有限公司正式發佈中證港股通機器人主題指數（代碼：932599），該指數旨在追蹤港股通範圍內機器人主題上市公司的整體表現。作為中國骨科醫療領域的領先企業，愛康醫療（1789.HK）成功獲納入該指數成份股，標誌著公司在醫療機器人領域的創新實力及商業化能力獲得市場認可，有望提升愛康醫療的投資者關注度。中證港股通機器人主題指數（932599.CSI）由中證指數有限公司編制，成份股數量為30隻，覆蓋港股通範圍內為機器人智慧化提供關鍵技術的企業。這些公司涉及感知、規劃決策、運動控制與執行等核心環節的軟體和硬體產品，包括感測器、人工智慧演算法、自動化設備等細分領域。該指數的推出，為投資者提供了便捷的工具，以把握機器人產業在工業、醫療、服務等應用場景中的增長機遇。愛康醫療是中國骨科植入物領域的創新領導者，自2003年成立以來，始終致力於通過前沿技術推動骨科醫療發展。比如，其自主研發的關節置換手術導航定位系統（K3+智慧手術機器人）就融合了高精度感知，符合該指數對“機器人智慧化”主題的嚴格篩選標準。愛康醫療的納入反映了其在港股通板塊中的代表性，以及醫療機器人行業在人口老齡化和技術升級趨勢下的高潛力。指數納入通常意味著成份股將獲得被動資金跟蹤，例如掛鉤該指數的ETF或衍生品。中證港股通機器人主題指數作為新興投資標的，有望吸引境內外機構資金配置。愛康醫療此次入選，或有助於擴大投資者基礎，優化股權結構，並進一步鞏固其在全球醫療科技競爭中的地位。隨著人工智慧與機器人技術的深度融合，中證港股通機器人主題指數有望成為港股市場的重要風向標。愛康醫療的加入，不僅是對其技術實力的肯定，也為整個醫療機器人賽道帶來積極信號。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TANAKA PRECIOUS METAL TECHNOLOGIES 建立了燒結金(Au)接合技術「AuRoFUSE(TM) Preforms」的轉印技術

acn

東京, 2026年3月3日 - (亞太商訊 via SeaPRwire.com) - 專注於產業用貴金屬展開業務的TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.（總公司：東京都中央區，執行總裁：田中 浩一朗）發表在燒結金(Au)接合技術「AuRoFUSE™ Preforms」中，建立了金凸塊※1的轉印技術。透過本技術，即使是面對具有複雜結構的半導體晶片或載板※2，也能進行AuRoFUSE™ Preforms（以下稱金凸塊）的形成。製作完成的金凸塊轉印基板轉印後的金凸塊因可轉印金凸塊而帶來的好處本技術的方法是事先製作已形成金凸塊的基板（以下稱轉印基板），再從中將凸塊轉印到目標半導體晶片或載板。在作為轉印基板使用的矽基板上設開口，並於該開口部形成金凸塊。​​藉由形成金凸塊以填充整個開口部，使其被基板保持住，故在操作過程中不用擔心金凸塊會脫落。另一方面，轉印時因加熱而使金凸塊收縮，開口部與金凸塊之間就會產生微小的間隙。因此，只要施加垂直力，即可輕易將其抽出。由於過去的金凸塊形成製程是採用在目標半導體晶片或載板上直接形成凸塊的方法，因此針對具有凹凸或貫穿孔等複雜形狀的目標物，存在光阻高度不一等課題，進而難以應對。在這次的轉印技術中，由於可另外製作金凸塊，並將金凸塊轉印至目標位置，因此也能應用於複雜形狀。另外，對於憂心剝離液等造成損傷，而難以進入微影※3製程的半導體晶片或載板，也能加以應對。轉印基板的製作以及轉印、接合製程(1) 準備作為轉印基板的矽基板(2) 在矽基板上塗佈光阻(3) 曝光和顯影至目標圖案(4) 在矽基板上以蝕刻鑽孔(5) 使用刮板等工具嵌入AuRoFUSE™(6) 在常溫及真空下乾燥AuRoFUSE™，並刮取光阻上多餘的金粒子(7) 剝離光阻後，轉印基板即完成(8) 將欲形成金凸塊的目標（半導體晶片或載板）對準轉印基板，進行10MPa、150℃、1分鐘的加壓加熱。隨後垂直提起基板，金凸塊即完成轉印(9) 將轉印後的基板以20MPa、200℃、10秒的加壓加熱進行接合過去的金凸塊形成製程關於燒結金接合技術「AuRoFUSE™ Preforms」　TANAKA所開發的「AuRoFUSE™ Preforms」是將由金微粒子與有機溶劑組成的膏材，預製形成凸塊形狀的接合技術。在200℃、20MPa、10秒的加壓加熱後，在壓縮方向顯示出約10％的收縮率，在水平方向上較少變形，具備足以承受實際應用的接合強度※4。再加上是以化學穩定性優異的金為主要成分，封裝後亦具高可靠性。本技術是一種能夠實現半導體配線微細化和多種晶片集成（高密度化）的技術，期待將為LED（發光二極體）和LD（半導體雷射）等光學元件，電腦和智慧型手機等數位元件上的應用，以及為車載零部件和MEMS等，近年來日益高漲的半導體小型化和高性能化需求做出貢獻。關於凸塊形成技術，過去是採用銲錫凸塊與電鍍凸塊為主要手法。不過，採用銲錫凸塊的話，由於隨著凸塊間距的微細化，銲錫材料在熔化時會往水平方向擴展，因此存在因電極間接觸而引起短路的風險。而電鍍凸塊雖然可做到窄間距化，但由於接合時需要相對較高的壓力，因此可能導致半導體晶片破損。本技術是為解決這些課題，並旨在應用於次世代高密度封裝及光電融合元件而進行開發。關於「AuRoFUSE™」以及TANAKA親自開發的金材料　「AuRoFUSE™」是在粒徑控制至次微米大小的金粒子中混合了有機溶劑的膏狀接合材料。與金的熔點（約1064℃）相比，可於約200℃的低溫下進行接合為其特徵。金是一種電阻低、熱傳導率非常高的材料。因此在處理大電流的功率半導體，以及發熱量大的高密度晶片中，能夠有效率地散熱並抑制能量損耗。另外，在貴金屬中也更是不易氧化，屬於穩定的物質，因此封裝後不易發生腐蝕或離子遷移（金屬移動而引起短路的現象），能長期維持高可靠性。TANAKA自創業以來，憑藉積累的貴金屬材料開發技術優勢，持續致力於開發像是金這類在半導體領域中扮演重要角色的貴金屬材料。另外，還擁有從原料採購到材料開發、製造及回收的一貫執行體制，在有效利用有限貴金屬資源的同時，為半導體技術發展以及實現永續社會做出貢獻。（※1） 凸塊：突起的電極（※2） 載板：用於承載半導體晶片並提供電氣與機械支撐的基板（※3） 微影：在基板上形成微細電路圖案的技術（※4） 接合強度：指剪斷強度（橫向載荷測試中的強度）關於TANAKATANAKA自1885年（明治18年）創業以來，營業範圍以貴金屬為中心，並以此展開廣泛活動。在日本國內，以最高水準的貴金屬交易量為傲的TANAKA，長年以來除了進行產業用貴金屬產品的製造和販售外，並提供資產用與珠寶用的貴金屬商品。本集團以貴金屬專業團隊之姿，旗下的國內外各集團公司協調合作，使製造、販售與技術一體化，並供應相關產品與服務。2024年度（2024年12月止）的合併營業額為8,469億日圓，擁有5,591名員工。產業事業全球網站https://tanaka-preciousmetals.com產品諮詢表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/tw/inquiries-on-industrial-products/新聞媒體諮詢處TANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/tw/inquiries-for-media/新聞稿: http://www.acnnewswire.com/docs/files/20260303_CT.pdf  Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Concord New Energy Signs MOU with Bain Capital-Backed Bridge Data Centre

acn

HONG KONG, March 3, 2026 - (ACN Newswire via SeaPRwire.com) – On 02 March 2026, Concord New Energy Group (“CNE Group”) signed a Memorandum of Understanding (MOU) in Singapore with Bridge Data Centres (BDC), a portfolio company of Bain Capital.Under the MOU, the parties will jointly explore diversified energy supply pathways integrating renewable energy and hydrogen solutions on a global basis to support the low-carbon transformation of data centre infrastructure. The collaboration includes the development of Singapore’s first barge-based hydrogen power generation solution designed specifically for artificial intelligence (AI) digital infrastructure.The partnership will encompass hydrogen power pathway studies, system integration design, energy storage deployment assessments, and optimization of power procurement mechanisms. Through these initiatives, both parties aim to enhance energy reliability, operational flexibility, and long-term sustainability for next-generation data centre campuses.CNE brings extensive expertise in renewable energy development and integrated energy systems, while BDC contributes leading operational capabilities in digital infrastructure. The collaboration is expected to accelerate the convergence of clean energy solutions and advanced computing infrastructure.As artificial intelligence and high-performance computing continue to reshape regional economies, this partnership will further support Singapore’s ambition to remain a leading digital hub powered by low-carbon energy.Bridge Data Centres (BDC)Headquartered in Singapore, Bridge Data Centres (BDC) is a leading hyperscale data centre platform in the Asia Pacific region backed by Bain Capital. The company focuses on the development and operation of high-performance digital infrastructure across multiple high-growth markets. BDC is committed to delivering resilient, reliable, and sustainable infrastructure solutions to support the rapid growth of cloud computing and artificial intelligence (AI) applications.Concord New Energy Group (CNE)Headquartered in Singapore, Concord New Energy Group is a renewable energy developer and operator listed on the Main Board of the Hong Kong Stock Exchange and the Singapore Exchange. With 20 years of experience in the renewable energy industry, CNE’s portfolio covers wind power, photovoltaic (PV) and energy storage projects. The Group has strong capabilities in project development, investment, construction and long-term asset management, and currently holds over 5GW of equity capacity globally. CNE remains committed to promoting the application of clean energy and providing integrated energy solutions to support sustainable development. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

協合新能源與貝恩資本旗下Bridge Data Centres簽署諒解備忘錄

acn

香港, 2026年3月3日 - (亞太商訊 via SeaPRwire.com) - 2026年3月2日，協合新能源集團（CNE 集團） 與貝恩資本旗下BDC在新加坡簽署諒解備忘錄（MOU）。根據備忘錄，雙方將在全球範圍內共同探索融合可再生能源與氫能解決方案的多元化能源供應路徑，支持數據中心基礎設施的低碳轉型, 包括提供新加坡首個專為人工智能數字基礎設施設計的駁船式氫能發電解決方案。合作內容包括：氫能發電路徑研究、系統集成設計、儲能部署評估，以及優化電力採購機制。雙方希望通過這些舉措，提升下一代數據中心園區的能源可靠性、運營靈活性與長期可持續性。協合新能源在可再生能源開發與綜合能源系統方面擁有專業優勢，BDC則在數字基礎設施領域具備領先運營能力，雙方合作旨在加速清潔能源與先進算力基礎設施的融合。隨著人工智慧與高性能計算持續重塑區域經濟，本次合作也將助力新加坡保持領先數字樞紐的地位，實現以低碳能源為支撐的發展目標。Bridge Data Centres（BDC）總部位於新加坡，貝恩資本（Bain Capital）旗下在亞太地區領先的超大規模數據中心平臺，專注於高性能數字基礎設施的開發與運營。公司業務覆蓋多個高增長市場，致力於提供韌性、可靠、可持續的基礎設施，支持雲計算與人工智慧應用的快速擴張。協合新能源集團（CNE）總部位於新加坡，是在香港交易所及新加坡交易所兩地主板上市的可再生能源開發商與運營商，擁有二十年可再生能源行業經驗，業務涵蓋風電、光伏及儲能項目。集團在項目開發、投資、建設及長期資產管理方面具備雄厚實力，目前在全球持有的權益裝機容量超過5 吉瓦（GW）。協合新能源始終致力於推動清潔能源應用，提供綜合能源解決方案，助力可持續發展。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Affiliate of Pacific Avenue Capital Partners to Acquire Care.com from IAC

acn

LOS ANGELES, CA, Mar 3, 2026 - (ACN Newswire via SeaPRwire.com) - Pacific Avenue Capital Partners ("Pacific Avenue"), a Los Angeles-headquartered private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced that an affiliate of Pacific Avenue has entered into an agreement to acquire Care.com from IAC Inc. (NASDAQ:IAC).Care.com is a leading platform and brand in the growing $400 billion market for family care, anchored by the largest online network of background-checked child and senior caregivers in the U.S.Care.com operates both a scaled consumer marketplace and an enterprise benefits platform. Since 2007, more than 45 million people have turned to Care.com to find child care, senior care, pet care and housekeeping support. Care.com also partners with more than 700 employers, including many of the Fortune 100, to deliver care-related benefits that combine access to the Care.com platform and comprehensive backup care solutions provided in-home, in-center and through camps and activities, along with a broader suite of care support solutions.As a standalone company, Care.com will accelerate its enterprise expansion while continuing to strengthen its consumer marketplace. With Pacific Avenue's investment and support, the Company will move faster on product innovation, scale its employer partnerships, and enhance the platform experience for the millions of families and caregivers who rely on it."We are thrilled to announce the Care.com transaction, the first investment in Pacific Avenue Fund II. The transaction aligns perfectly with Pacific Avenue's track record of executing corporate carve-outs to acquire market-leading businesses. Care.com is an industry leader with a brand built on trust, a strong reputation, and a proven leadership team. Care.com has a clear path for growth as an independent, standalone company. We're excited to work with Brad, Michelle, and the Care.com team to unlock the company's full potential in serving families, caregivers, and its enterprise partners."- Chris Sznewajs, Founder and Managing Partner of Pacific Avenue"Caregiving is foundational to how families live and how businesses operate," said Brad Wilson, CEO of Care.com. "This partnership allows us to deepen our support for families and caregivers while expanding the ways we serve employers who recognize that caregiving is a workforce issue. We're entering this next chapter with strength, clarity, and a renewed commitment to building the most beloved platform for care.""Care.com enters this next chapter with a profitable foundation. This transaction positions us to further invest in our platform, expand our employer partnerships, and scale efficiently while maintaining the financial discipline that has strengthened our performance," said Michelle Arbov, Chief Financial Officer of Care.com.The transaction is subject to customary closing conditions and is expected to be completed in the first half of 2026.Moelis & Company LLC served as exclusive financial advisor to Pacific Avenue. Weil, Gotshal & Manges LLP served as legal advisor to Pacific Avenue.KPMG LLP provided accounting and tax advisory services. J.P. Morgan Securities LLC acted as exclusive financial advisor to IAC and Latham and Watkins LLP served as legal counsel to IAC.About Pacific Avenue Capital PartnersPacific Avenue Capital Partners is a global private equity firm headquartered in Los Angeles with an office in Paris. The firm is focused on corporate divestitures and other complex situations in the middle market. Pacific Avenue has extensive M&A and operations experience, allowing the firm to navigate complex transactions and unlock value through operational improvement, capital investment, and accelerated growth. Pacific Avenue takes a collaborative approach in partnering with strong management teams to drive lasting and strategic change while assisting businesses in reaching their full potential. Pacific Avenue has approximately $3.8 billion of Assets Under Management (AUM) as of September 30, 2025. For more information, please visit www.pacificavenuecapital.com.Contact InformationChris BaddonManaging Directorcbaddon@pacificavenuecapital.comSOURCE: Pacific Avenue Capital Partners Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

太平洋大道資本合夥公司旗下子公司將向IAC收購Care.com

acn

加州洛杉磯, 2026年3月3日 - (亞太商訊 via SeaPRwire.com) - 太平洋大道資本合夥公司（Pacific Avenue Capital Partners，簡稱「太平洋大道」），這家總部位於洛杉磯的私募股權公司專注於中型市場的企業分拆及其他複雜交易，今日宣布其關聯公司已與IAC Inc.（納斯達克代碼：IAC）達成協議，將收購Care.com。Care.com 是家庭照護領域中規模龐大的平台與品牌，深耕於價值4,000億美元的成長型市場，其核心優勢在於擁有全美規模最大的線上背景審查兒童及長者照護人員網絡。Care.com 同時營運大規模消費者市場平台與企業福利平台。自2007年以來，已有超過4,500萬人透過Care.com尋求兒童照護、長者照護、寵物照護及家務支援服務。Care.com 同時與逾700家企業合作（包含眾多《財星》百大企業），提供結合平台服務與全方位後備照護方案的福利方案，涵蓋居家照護、中心照護、營隊活動支援，以及更廣泛的照護支援服務。作為獨立公司，Care.com 將加速企業業務拓展，同時持續強化消費者市場平台。在太平洋大道基金的投資與支持下，公司將加速產品創新步伐、擴大雇主合作規模，並為數百萬依賴該平台的家庭與照護者提升使用體驗。「我們欣喜宣布Care.com交易案，此乃太平洋大道基金二期首筆投資。此交易完美契合本基金過往執行企業分拆收購市場領導企業的成功紀錄。Care.com作為行業領軍者，憑藉值得信賴的品牌形象、卓越聲譽及經驗豐富的領導團隊奠定根基。作為獨立運營的企業，Care.com擁有清晰的成長路徑。我們期待與Brad、Michelle及Care.com團隊攜手，充分釋放該公司在服務家庭、照護者及企業夥伴方面的潛能。」——太平洋大道創始人暨管理合夥人克里斯·斯涅瓦伊斯「照護服務是家庭生活與企業運作的基石，」Care.com執行長布拉德·威爾遜表示，「此合作將深化我們對家庭與照護者的支持，同時拓展服務模式，協助企業正視照護需求對勞動力構成的挑戰。我們將以堅實實力、清晰願景及全新承諾，邁向打造最受愛戴照護平台的新篇章。」「Care.com以盈利基礎邁入新篇章。本次交易使我們得以持續投資平台建設、拓展雇主合作網絡並實現高效擴張，同時維持強化業績的財務紀律。」Care.com財務長米歇爾·阿博夫表示。本交易須符合慣例交割條件，預計於2026年上半年完成。Moelis & Company LLC擔任Pacific Avenue獨家財務顧問，Weil, Gotshal & Manges LLP擔任其法律顧問。KPMG LLP提供會計與稅務諮詢服務，J.P. Morgan Securities LLC擔任IAC獨家財務顧問，Latham and Watkins LLP擔任IAC法律顧問。關於太平洋大道資本合夥公司太平洋大道資本合夥公司是一家全球性私募股權公司，總部位於洛杉磯，並在巴黎設有辦事處。該公司專注於中型市場的企業資產剝離及其他複雜情境。憑藉深厚的併購與營運經驗，太平洋大道能主導複雜交易，並透過營運優化、資本投入及加速成長釋放企業價值。公司採取協作模式，與實力雄厚的管理團隊攜手推動持久戰略變革，協助企業充分釋放潛能。截至2025年9月30日，太平洋大道管理資產規模（AUM）約達38億美元。更多資訊請瀏覽官網：https://pacificavenuecapital.com/。聯絡資訊Chris BaddonManaging Director cbaddon@pacificavenuecapital.comSOURCE: Pacific Avenue Capital Partners Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com